


# Spotlight On: Tocilizumab


March 31, 2025

**Technology:** Tocilizumab is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor that inhibits IL-6 signaling and hinders IL-6's pro-inflammatory effects.

## Tocilizumab Timeline



## Tocilizumab Challenged Claim Types in IPR and Litigation\*



\*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints. Joinder counted separately.

# Spotlight On: Tocilizumab

March 31, 2025

|            | <i>Fresenius Kabi v. Chugai</i><br>IPR2021-01024<br>Settled after institution | <i>Fresenius Kabi v. Chugai</i><br>IPR2021-01025<br>Settled after institution | <i>Fresenius Kabi v. Chugai</i><br>IPR2021-01288,<br>IPR2021-01542<br>Settled after institution | <i>Fresenius Kabi v. Chugai</i><br>IPR2021-01336<br>Settled after institution | <i>Fresenius Kabi v. Chugai</i><br>IPR2022-00201<br>Settled after institution | <i>Celltrion v. Chugai</i><br>IPR2022-00578<br>Final Written Decision (All challenged claims unpatentable);<br>Appeal 24-1115 voluntarily dismissed | <i>Celltrion v. Chugai</i><br>IPR2022-00579<br>Final Written Decision (All challenged claims unpatentable);<br>Appeal 24-1111 voluntarily dismissed | <i>Fresenius Kabi v. Chugai</i><br>IPR2022-01065<br>Settled before institution | <i>Genentech v. Biogen</i><br>1:23-cv-11573<br>(D. Mass.)<br>Settled |
|------------|---|---|---|---|---|---|---|--|--|
| 7,332,289  |   |   |   |   |   |   |   |  | x  |
| 7,521,052  | x   |   |   |   |   |   |   |  | x  |
| 8,398,980  |   |   |   |   |   |   |   |  | x  |
| 8,512,983  |   |   |   |   |   |   |   |  | x  |
| 8,574,869  |   |   |   |   |   |   |   |  | x  |
| 8,580,264  |   |   | x   |   |   | x   |   |  |  |
| 8,734,800  |   |   |   |   |   |   |   |  | x  |
| 9,714,293  |   |   |   |   |   |   |   |  | x  |
| 9,750,752  |   |   |   |   | x   |   |   |  |  |
| 9,902,777  |   |   |   |   |   |   |   |  | x  |
| 10,017,732 |   |   |   |   |   |   |   |  | x  |
| 10,231,981 |   |   |   |   |   |   |   | x  |  |
| 10,336,983 |   |   |   |   |   |   |   |  | x  |
| 10,501,769 |   |   |   |   |   |   |   |  | x  |
| 10,662,237 |   |   |   |   |   |   |   |  | x  |
| 10,676,710 |   |   |   |   |   |   |   |  | x  |
| 10,744,201 |   | x   |   |   |   |   |   |  | x  |
| 10,829,732 |   |   |   |   |   |   |   |  | x  |
| 10,874,677 |   |   |   | x   |   |   | x   |  |  |
| 10,982,003 |   |   |   |   |   |   |   |  | x  |
| 11,021,728 |   |   |   |   |   |   |   |  | x  |
| 11,078,294 |   |   |   |   |   |   |   |  | x  |
| 11,136,610 |   |   |   |   |   |   |   |  | x  |
| 11,377,678 |   |   |   |   |   |   |   |  | x  |